For sufferers with newly identified a number of myeloma (NDMM) receiving dexamethasone induction, dose reductions don’t negatively impression survival, in keeping with a research printed on-line Jan. 2 in Blood.
Rahul Banerjee, M.D., from the Fred Hutchinson Most cancers Heart in Seattle, and colleagues performed a secondary pooled evaluation of the SWOG 0777 and SWOG 1211 research, which examined lenalidomide and dexamethasone alone, with or with out bortezomib and with or with out elotuzumab for NDMM. In all arms, the deliberate dexamethasone depth was 40 to 60 mg weekly. Sufferers had been labeled as full-dose dexamethasone all through induction (FD-DEX) or lowered-dose dexamethasone or discontinuation (LD-DEX), permitted for grade 3+ toxicities per each research protocols.
The LD-DEX group included 373 sufferers (69%) of the 541 evaluated. The researchers discovered that progression-free survival (PFS) and total survival (OS) didn’t differ between the FD-DEX and LD-DEX teams. Within the multivariate fashions, predictors of PFS and OS had been remedy arm, age 70 years or older, and thrombocytopenia.
“Dexamethasone dose reductions
A number of authors disclosed ties to the biopharmaceutical business.
Extra data:
Rahul Banerjee et al, Dexamethasone dose depth doesn’t impression outcomes in newly identified a number of myeloma: a secondary SWOG evaluation, Blood (2024). DOI: 10.1182/blood.2024025939
Journal data:
Blood
© 2025 HealthDay. All rights reserved.
Quotation:
Decrease dexamethasone dose doesn’t impair survival in a number of myeloma (2025, January 24)
retrieved 24 January 2025
from https://medicalxpress.com/information/2025-01-dexamethasone-dose-impair-survival-multiple.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
